PHBBF (Pharmaron Beijing Co) Receipts from Customers

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHBBF Pharmaron Beijing Co Ltd PHBBF
84 GF Score
Price $1.93
GF Value $1.60
! 4 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Receipts from Customers?

Receipts from Customers only applicable to companies reporting Cash Flow from Operations in direct method.

PHBBF
84GF Score
Pharmaron Beijing Co Ltd PHBBF
Receipts from Customers is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of $1.93 is trading 20.6% above its estimated GF Value™ of $1.60.

Key valuation signals for PHBBF:

  • Receipts from Customers:
  • GF Value™: $1.60 vs. price of $1.93 (20.6% above fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmaron Beijing Co Business Description

Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a China-based contract research, development, and manufacturing organization serving the life sciences industry. It provides integrated drug discovery and development services, including synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism studies. Its operating segments comprise laboratory services, CMC (small molecule CDMO) services, clinical development services, and biologics and cell and gene therapy services. Laboratory services generate the largest share of revenue. The company supports pharmaceutical and biotechnology clients worldwide across the drug discovery, preclinical, and clinical development stages, as well as commercial manufacturing. It operates research and manufacturing facilities in China, the United States, and the United Kingdom, serving customers in North America, Europe, and Asia. Revenue is primarily derived from fee-for-service research contracts and manufacturing agreements with pharmaceutical and biotech companies.
84GF Score

Get the complete analysis for PHBBF

Receipts from Customers is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93
Price
$1.60
GF Value